Grazia Aleppo, United States of America
Northwestern University Feinberg School of MedicinePresenter of 3 Presentations
GLYCEMIC IMPROVEMENT IN 1,311 PATIENTS WITH TYPE 1 DIABETES (T1D) USING THE OMNIPOD DASH® INSULIN MANAGEMENT SYSTEM OVER FIRST 90 DAYS OF USE
Abstract
Background and Aims
Clinical outcomes describing real-world use of various devices by people with T1D are important to support decision-making. This retrospective study characterized patient-reported clinical outcomes of people with T1D in the United States before (baseline) and 90 days after (follow-up) initiation of the tubeless Omnipod DASH® Insulin Management System.
Methods
The primary outcome was change in self-reported HbA1c levels from baseline to follow-up. Secondary outcomes were change in self-reported total daily dose (TDD) of insulin and self-reported frequency of hypoglycemic events (HE) per week (#/week <70 mg/dL). Outcomes were assessed overall, by prior treatment modality (MDI or CSII), and by age (<18y, ≥18y).
Results
Patients (n=1,311) were divided into 2 age groups (<18y: n=405, ≥18y: n=906) aged 9.9±4.2y and 45.9±16.9y (mean±SD) and 49.6% and 60.7% female, respectively (Table 1). The overall change in self-reported HbA1c at follow-up was -0.9±2.0% for patients <18y (p<0.0001) and -0.8±1.4% for patients ≥18y (p<0.0001). The change in HbA1c for prior MDI and prior CSII users was ‑1.0±2.1% (p<0.0001) and -0.4±1.3% (p>0.05) in patients <18y, and -0.9±1.6% (p<0.0001) and -0.5±1.0% in patients ≥18y (p<0.0001), respectively. Overall change in TDD of insulin for patients <18y and ≥18y was ‑1.7±10.9U/d (p>0.05) and -12.8±27.7U/d (p<0.0001) and the self-reported HE frequency decreased significantly by -1.4±2.9 (p<0.0001) and -1.9±3.2 (p<0.0001) episodes per week, respectively.
Conclusions
This large cohort of patients with T1D using the Omnipod DASH® Insulin Management System exhibited significant reductions in HbA1c, TDD of insulin, and number of HE after 90 days of use across both age groups.